Compare WEST & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEST | CSTL |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.3M | 722.8M |
| IPO Year | 2022 | 2019 |
| Metric | WEST | CSTL |
|---|---|---|
| Price | $9.85 | $33.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.00 | ★ $45.22 |
| AVG Volume (30 Days) | ★ 338.6K | 319.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,188,952,000.00 | $344,229,000.00 |
| Revenue This Year | $3.92 | $8.49 |
| Revenue Next Year | $7.72 | $10.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.76 | 3.66 |
| 52 Week Low | $3.59 | $17.72 |
| 52 Week High | $10.19 | $44.28 |
| Indicator | WEST | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 79.26 | 47.52 |
| Support Level | $7.66 | $31.44 |
| Resistance Level | $10.00 | $34.23 |
| Average True Range (ATR) | 0.38 | 1.69 |
| MACD | 0.17 | -0.13 |
| Stochastic Oscillator | 94.82 | 21.52 |
Westrock Coffee Co is an integrated coffee, tea, flavors, extracts, and ingredients solutions provider mainly in the United States. Additionally, it offers coffee sourcing, supply chain management, product development, roasting, packaging, and distribution services to retail, foodservice, restaurant, convenience store, travel center, non-commercial account, and hospitality industries around the world. The company's reportable segments are: Beverage Solutions and Sustainable Sourcing and Traceability. It generates maximum revenue from the Beverage Solutions segment, which offers beverage solutions, including coffee, tea, flavors, extracts, and ingredients. Geographically, the company generates maximum revenue from its business in the United States and the rest from other countries.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.